An interventional study of The ORANEAT program in Antibacterial Agents, sponsored by University of Lorraine. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Lorraine · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To tackle antimicrobial resistance (AMR), i.e., one of the top 10 global health threats, antimicrobial stewardship (AMS) programs, i.e., coherent sets of actions promoting responsible use of antimicrobials, have been developed. Despite growing evidence about their effectiveness, their implementation remains suboptimal. Qualifying as complex interventions, these programs are prone to interactions with context, potentially compromising their successful transfer to other settings. AMR remains critical in French nursing homes (NHs). AMS programs have proven effective in reducing antimicrobial resistance in hospitals and in NHs. However, the evidence is inconsistent across studies in NHs and mostly based on North American and North European AMS programs and studies, raising concerns about transferability that might occur while implementing such AMS programs in French NHs. For instance, health systems and NH funding and organization vary considerably across countries, resulting in potential key determinants driving antibiotic use in such facilities in some countries that might remain untargeted by AMS programs developed in other countries. In addition, inconsistent effectiveness of AMS programs in NHs might also result from implementation issues, raising concerns about the strategies used to implement such programs. Based on extensive logic models linking psychosocial and organizational determinants driving antibiotic use in NHs of diverse countries, we developed and pilot-tested a customizable AMS program (i.e., the ORANEAT program) suited to French NHs, including three major components: (i) a contextual diagnostic regarding AMS in the targeted NH; (ii) based on the results of the contextual diagnostic, a bundle of tools selected from an AMS-toolkit including actions and tools suited to French NH setting; and (iii) implementation support relying on French structures involved in tackling AMR (i.e., CRAtb and CPias).
This study aims to assess the effectiveness, the sustainability, the implementation, and the transferability of the ORANEAT program in French NHs, using a mixed-method approach (quantitative and qualitative data). A cluster randomized controlled trial with two arms (ORANEAT program vs. no specific intervention) will be conducted; the cluster being the NH. The primary outcome to measure the effectiveness is total antibiotic use expressed in defined daily doses/1000 resident-days/month.
University of Lorraine is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Nursing homes
Inclusion criteria:
Exclusion criteria:
Residents (Outcomes 1 to 4 and outcome 12)
Inclusion criteria:
Exclusion criteria:
/
Healthcare professionals (Outcomes 11, 13 and 15)
Inclusion criteria:
Exclusion criteria:
Nursing homes in the experimental group will receive the ORANEAT antibiotic stewardship program.
Other: The ORANEAT program
Nursing homes in the control group will not receive the ORANEAT antibiotic stewardship program ("usual care").
The ORANEAT multifaceted customizable antibiotic stewardship program includes (i) a contextual diagnostic regarding AMS in the targeted NH; (ii) based on the results of the contextual diagnostic, a bundle of tools selected from an AMS-toolkit including actions and tools suited to French NH setting and covering the main CDC domains of AMS in NHs; and (iii) implementation support relying on French structures involved in tackling AMR (i.e., CRAtb and CPias).
Overall antibiotic prescription rate (DDD)
Overall antibiotic prescription rate expressed in Defined Daily Doses (DDD)/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.
Time frame: 12 months
Overall antibiotic prescription rate (number of prescriptions)
As part of a sensitivity analysis: Overall antibiotic prescription rate expressed in number of prescriptions/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.
Time frame: 12 months
Effectiveness of the intervention - broad-spectrum antibiotics
Broad-spectrum antibiotic prescription rate expressed in Defined Daily Doses (DDD)/1000 resident-days/month. Broad-spectrum antibiotics include quinolones and 3rd-generation cephalosporins. Measured using data from the Health Insurance reimbursement database.
Time frame: 12 months
Effectiveness of the intervention - appropriateness of antibiotic prescriptions
Proxy indicators reflecting the appropriateness of antibiotic use in nursing homes (Asquier-Khati et al. 2023, doi:10.1093/jacamr/dlad037). These proxy indicators assess the appropriateness of prescriptions for urinary tract infections, seasonal variations in prescriptions, repeated prescriptions of fluoroquinolones, cephalosporins' route of administration, duration of treatment, rate of second-line antibiotics, and co-prescriptions with non-steroidal anti-inflammatory drugs.
Time frame: 12 months
Safety of the intervention
Number of hospital admissions/1000 resident-days and number of deaths/1000 resident-days among nusing home residents. Measured using data from the Health Insurance reimbursement database.
Time frame: 12 months
Sustainability of the effectiveness
Overall antibiotic prescription rate expressed in Defined Daily Doses (DDD)/1000 resident-days/month. As part of a sensitivity analysis: Overall antibiotic prescription rate expressed in number of prescriptions/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.
Time frame: 24 months
Context of the intervention - nursing homes' characteristics
Nursing homes' staff resources (number of coordinating physicians, nurses, assistant nurses and general practitioners). Measured using data collected by the research team through ad hoc standardized activity reports.
Time frame: At inclusion
Context of the intervention - nursing homes' geographic areas' characteristics
Characteristics of the geographic areas of the nursing homes (type of area: rural/semi-urban/urban; access to general practioners in the area according to the Local Potential Accessibility Index, which considers the number of general practioners, their level of activity, the age of the population, and the distance to GPs' offices within the municipality ). Measured using data from administrative public databases.
Time frame: At inclusion
Adoption of the intervention
Number of nursing homes included / number of nursing homes invited to participate in the intervention group \* 100, by stratum. Measured using data collected by the research team through ad hoc standardized activity reports.
Time frame: 12 months
Reach of the target population - contextual diagnosis
For each profesionnal category (nursing home coordinating physician or nurse, nurses, assistant nurses and referring general practitioners), participation rate (%) in the contextual diagnostic questionnaire of the ORANEAT program (first component of the program), calculated as as the number of completed questionnaires divided by the total number of professionals in that category x 100.
Time frame: 12 months
Reach of the target population - antimicrobial stewardship tools/actions
Proportion of nurses and assistant nurses attending at least one training session; proportion of referring general practitioners contacted at least once regarding the ORANEAT program by the external or the internal facilitators; number of tools distributed (number of copies provided to the nursing home, for each tool); proportion of nursing homes that developed at least one tool as part of the "tool development" action of the ORANEAT program. Measured using data collected by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Fidelity of the intervention - antimicrobial stewardship tools
Number of tools used / number of tools included in the bundle of tools, for each bundle. Measured using data collected by the by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Fidelity of the intervention - categories of antimicrobial stewardship tools
Number of categories of the antimicrobial stewardship tools/actions implemented in the nursing home according to the contextual diagnostic tool of the ORANEAT program and their evolution over 12 months. Categories are defined according to the Centers for Disease Control and Prevention (CDC) core elements of antibiotic stewardship for nursing homes. Data collected through the questionnaires of the contextual diagnostic.
Time frame: At 3 months, 6 months, 9 months and 12 months
Dose of intervention - score of exposure to the intervention
Score of exposure to each component of the ORANEAT program. This composite measure will capture the intensity of exposition to each component of the program in each nursing home (i.e., the contextual diagnosis, the exposition to the tools/actions, and the implementation strategies). Measured using data collected by the research team through ad hoc standardized activity reports, the questionnaires of the contextual diagnostic and annual activity reports from the local antimicrobial stewardship teams.
Time frame: Through the end of the intervention, an average of 12 months
Dose of intervention - antimicrobial stewardship tools
Number of tools used for each target population. Measured using data collected by the by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Dose of intervention - implementation support
Number of meetings with the internal and external facilitators held as part of the implementation support of the ORANEAT program (third component of the program). Measured using data collected by the by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Dose of intervention - time to implement the program
Average time (days) between validation of the pack with the internal facilitators and the date when all tools are reported as used. Measured using data collected by the by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Adaptation of the intervention
Number of tools withdrawn from the bundle of tools or modified (in form and/or content) or added / number of tools initially proposed (for each bundle of tools and overall). Measured using data collected by the by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Users' experiences of the intervention
Users' experiences with the ORANEAT program assessed among coordinating physicians/nurses, nurses, assistant nurses and general practitioners using a questionnaire UREMs (User Reported Experience Measures) adapted from PREMs (Patient Reported Experience Measures) developed by the research team. This questionnaire was designed to measure the users reported experience of the intervention. A score ranging from 0 to 100 will be calculated; higher score means better experience.
Time frame: 12 months
Sustainability of the intervention
Sustainability of the ORANEAT program assessed among coordinating physicians/nurses, nurses, assistant nurses and general practitioners using the NoMAD questionnaire (questionnaire based on the normalization process theory \[NPT\], measuring the normalization of complex healthcare interventions - Finch et al. 2018 - doi: 10.1186/s12874-018-0591-x). The NoMAD questionnaire includes three general items on the intervention answered on an 11-point Likert scale ranging from 0 to 10, and 20 items representing the four key constructs of NPT: coherence (4 items), cognitive participation (4 items), collective action (7 items), and reflexive monitoring (5 items) answered on a 5-point Likert scale ranging from strongly agree to strongly disagree. Mean scale scores will be calculated for each NoMAD construct as well as for the overall scale (20 items); higher scores mean higher degree of normalization.
Time frame: 12 months
Mechanisms of impact of the intervention - prescriptions of urine cultures
Number of urine cultures prescribed/1000 resident-days/month. Measured using data from the Health Insurance reimbursement database.
Time frame: 12 months
Mechanisms of impact of the intervention - nursing home professionals' knowledge, attitudes, practices and motivation
Nursing home professionals' (coordinating physicians/nurses, nurses, assistant nurses and general practitioners) knowledge, attitudes, practices and motivation towards AMS. For each component (knowledge, attitudes, practices and motivation), a score ranging from 0 to 100 will be calculated; higher scores means more favorable position towards AMS. Data collected through the questionnaires of the contextual diagnostic.
Time frame: At inclusion, 6 and 12 months
Costs of the intervention
Cost associated with the work provided by the professionals responsible for the implementation support, with printing and sending the ORANEAT program tools to the nursing homes, etc. Measured using data collected by the by the research team through ad hoc standardized activity reports.
Time frame: Through the end of the intervention, an average of 12 months
Context, mechanisms of impact, sustainability, implementation, and transferability of the intervention
Observations, semi-structured interviews, focus groups with professionals involved in the implementation of the ORANEAT program (coordinating physicians/nurses, nurses, assistant nurses, general practitioners, professionals responsible for the implementation support…).
Time frame: Through the end of the intervention, an average of 12 months
Plan to share: No — IPD Sharing Plan Description: N/A
Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Dec 2025 → Apr 2026, primary completion Jan 2027 → Jul 2027 and completion Jan 2028 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Lorraine